Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
Create a narrative
Our community narratives are driven by numbers and valuation.
Create a narrative
Weekly Picks
Citigroup
CH
ChadWisperer
Community Contributor
Pole position to benefit from GENIUS Act
The passing of the GENIUS Act establishes a clear regulatory framework for stablecoins, allowing banks like Citi to issue their own stablecoins; Citi Token Services lets Citi position itself as the "killer app" for institutional cross-border payments, absorbing complexities and offering instant, cost-effective solutions; Core business is firing on all cylinders , with record performances in Markets and Wealth, significant share gains in Investment Banking (especially M&A, LevFin, and sponsors), and robust growth in Services and U.S. Personal Banking, all contributing to strong revenue momentum; Highly capital efficient returning $3 billion in capital during the quarter , including $2 billion in share repurchases, part of our $20 billion repurchase plan with a goal of 11% Return on tangible equity (ROTE or ROTCE). ✨ Chat with this narrative: https://notebooklm.google.com/notebook/aa2a6c92-6bd1-495e-beb5-d8d4e6525410 (believe a Google account is required) Background Citigroup Inc.
View narrative
US$233.04
FV
59.7% undervalued
intrinsic discount
6.00%
Revenue growth p.a.
Set Fair Value
9
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
3 days ago
author updated this narrative
IREN
KA
kapirey
Community Contributor
IREN will transform from bitcoin miner to leader in AI infrastructure
Key Highlights Financial Performance (Q3 FY25) Record Revenue : $148.1 million Record Adjusted EBITDA : $83.3 million Record EBITDA : $82.7 million Profit After Tax : $24.2 million Avg. Operating Hashrate : 29.4 EH/s Strong Margins : All-in cash cost per BTC mined at $41k vs.
View narrative
US$21.48
FV
13.5% undervalued
intrinsic discount
50.00%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
8 days ago
author updated this narrative
XRF Scientific
RO
Robbo
Community Contributor
Behind the Assay: XRF Scientific’s Role in Modern Mining Economics
There’s an old saying that in a gold rush, those who make the money are the ones selling the shovels; and mining service companies have indeed proven to be shrewd investments historically. XRF Scientific holds a strong niche in sample preparation equipment and consumables used in X-ray fluorescence (XRF) and X-ray diffraction (XRD) analysis, which are essential in determining the quality and purity of materials.
View narrative
AU$2.10
FV
1.4% undervalued
intrinsic discount
9.68%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
2 days ago
author updated this narrative
All companies
Popular
Undervalued
Overvalued
Community Investing Ideas
Load previous narratives
Steadfast Group
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Investments In InsurTech And International Expansion Will Improve Operational Efficiency
Key Takeaways Competitive pricing, premium rate increases, and strategic acquisitions in international markets bolster revenue growth and operational efficiencies. Technology investments and management strengthening are anticipated to improve net margins through streamlined operations and enhanced risk management.
View narrative
AU$6.65
FV
10.2% undervalued
intrinsic discount
4.39%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
13
users have followed this narrative
7 days ago
author updated this narrative
Aspen Pharmacare Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Commercial Pharma And GLP-1 Expansion Will Empower Future Progress
Key Takeaways Steady commercial pharma growth through strategic market focus in China and Russia enhances revenue stability. GLP-1 and insulin manufacturing expansion offers substantial long-term revenue and margin growth potential.
View narrative
R156.99
FV
25.5% undervalued
intrinsic discount
4.25%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
21
users have followed this narrative
7 days ago
author updated this narrative
Neoenergia
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Tariff Reviews And Projects Will Advance Operations Despite Risks
Key Takeaways Successful tariff reviews and completed transmission projects are expected to strengthen earnings growth by enhancing revenue streams. Deleveraging through asset sales and partnerships aims to improve financial stability, while organic growth in distribution drives consistent revenue post-2025.
View narrative
R$29.62
FV
21.7% undervalued
intrinsic discount
-3.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
7 days ago
author updated this narrative
Valmet Oyj
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Renewing Operations And DNAe Will Streamline Supply Integration
Key Takeaways Simplifying operations and integrating supply units are expected to boost efficiency, cost competitiveness, and profitability through enhanced margin control. Strong growth in Services and Automation segments and new automation solutions signal robust revenue growth potential and market expansion.
View narrative
€28.59
FV
7.4% undervalued
intrinsic discount
2.59%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
26
users have followed this narrative
7 days ago
author updated this narrative
Logista Integral
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Pharma Italia Integration And SGEL Libros Acquisition Drive Growth, But Declining Tobacco Sales Pose Risks
Key Takeaways Logista's diversification strategy and acquisitions in sectors like pharmaceuticals could drive future revenue growth and strengthen its market position. Effective management of tobacco-related factors and a robust dividend policy suggest stable shareholder returns and potential attractiveness despite external economic challenges.
View narrative
€32.86
FV
16.5% undervalued
intrinsic discount
-47.69%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
22
users have followed this narrative
7 days ago
author updated this narrative
Brunswick
AN
AnalystLowTarget
Consensus Narrative from 16 Analysts
Tariff Risks Will Pressure Margins While Cost Cuts Support Stability
Key Takeaways Significant potential tariff costs and inability to pass them on to consumers could compress net margins, impacting earnings, especially in the Propulsion business. Declines in value segment boat brands and macroeconomic pressures could reduce revenues due to lower production volumes and challenges in entry-level products.
View narrative
US$42.00
FV
51.6% overvalued
intrinsic discount
2.98%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
7 days ago
author updated this narrative
SCHOTT Pharma KGaA
AN
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
High Demand For GLP-1 Drug Storage Will Spur Future Expansion
Key Takeaways Strong focus on higher-value solutions and expansion projects are key to boosting revenue, margins, and production capacity. Strategic partnerships and demand for drug containment solutions drive revenue growth, with recovery in core markets supporting earnings and cash flow.
View narrative
€28.89
FV
14.7% undervalued
intrinsic discount
10.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
7 days ago
author updated this narrative
Hexcel
AN
AnalystLowTarget
Consensus Narrative from 16 Analysts
Supply Chain Delays Will Challenge Airbus Production But Open Opportunities
Key Takeaways Hexcel's revenue and profitability are under pressure due to supply chain delays and reduced operating leverage in aerospace production. Tariff uncertainties and delayed aircraft production rates may impact Hexcel's cost structure and financial recovery.
View narrative
US$50.00
FV
21.6% overvalued
intrinsic discount
6.49%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
7 days ago
author updated this narrative
Vibra Energia
AN
AnalystConsensusTarget
Consensus Narrative from 15 Analysts
New Service Stations And BR Mania Stores Will Expand Market Presence But High Leverage May Strain Future Operations
Key Takeaways Expansion into new markets and improved reseller relationships are expected to enhance revenue, net margins, and competitiveness. Strategic cost reductions and efficiency improvements will likely boost earnings, cash flow, and financial stability.
View narrative
R$27.63
FV
27.7% undervalued
intrinsic discount
2.52%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
7 days ago
author updated this narrative
Value any company in seconds
Popular companies